Swarm Oncology Ltd. has emerged from stealth with a focus on advancing novel T-cell therapies to achieve long-term remission in patients with advanced solid cancers.

Pancreatic cancer has the worst survival rates among all solid tumor types, and its incidence is increasing. Hypoxic conditions that arise from an imbalance between increased oxygen consumption and an inadequate oxygen supply play a key role in several solid tumors. This impacts the proliferation, migration, apoptosis and metabolism of tumor cells; hypoxia is considered a key contributor to chemoresistance in cancer cells.

Silexon Intelligent Technology Co. Ltd. has identified GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Janssen Pharmaceutica NV has divulged mucosa associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer.

Genescience Pharmaceuticals Co. Ltd. has synthesized cellular tumor antigen p53 (TP53) (Y220C mutant) reactivators reported to be useful for the treatment of cancer.

Kexing Biopharm Co. Ltd. has outlined progress in its cachexia and autoimmune pipelines, built upon its Kx-Body antibody technology platform and Kx-Fusion fusion protein technology platform.

Adenoid cystic carcinoma (ACC) is a rare malignancy of the secretory glands with a high tendency to invade adjacent tissue and spread to the lung, bone or liver. No treatments other than surgery or radiotherapy are available, so new therapeutic strategies are urgently needed.

Ohio State University has described NADH-ubiquinone oxidoreductase (complex I) inhibitors acting as radiosensitizers for radiation therapy reported to be useful for the treatment of cancer.